Ozempic, designed for type-2 diabetes treatment, has garnered widespread attention for its potential to aid weight loss in obese individuals. In Australia, where obesity affects 30% of the population, it has sparked significant interest and Novo Nordisk, the company behind it, has seen its share price surge by almost 500% in 5 years. While there are other similar drugs on the market, Ozempic is the OG. Which is why we are delving into it for News Club... Club Picks: This podcast on ABC Radio National’s Life Matters program includes an interview with podcaster Claire Murphy. S The invention of these drugs has had - and will continue to have - economic impacts. This episode of The Economist’s Money Talks podcast goes through that, and the industry that’s booming off the back of them. You can’t go far in this discussion without mentioning Oprah Winfrey… The US multi-media legend has had a decades-long struggle with her weight. She’s even made a show about it - Shame, Blame and the Weight Loss Revolution - a clip is here. Hosts: Claire Kimball & Kate Watson Producer: Annelise Taylor

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related